Insider · CIK 0001590973

Flagship Ventures Fund IV-Rx, L.P.

CIK 0001590973 Name as filed on the most recent filing

Filed as Flagship Ventures Fund IV-Rx, L.P. (16)

75 transaction lines · from 16 filings · filed 2014-02-13 to 2022-06-01 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2022-05-27 P, Open-market purchase Evelo Biosciences, Inc.EVLO 5 lines 39,999,998, acquired Open Form 4 filing 0000899243-22-020533
2022-03-16 P, Open-market purchase Axcella Health Inc.AXLA 3 lines 12,069,999, acquired Open Form 4 filing 0000899243-22-011535
2021-02-02 P, Open-market purchase Evelo Biosciences, Inc.EVLO 4 lines 1,950,000, acquired Open Form 4 filing 0000899243-21-004962
2020-06-29 P, Open-market purchase Evelo Biosciences, Inc.EVLO 4 lines 17,499,998, acquired Open Form 4 filing 0000899243-20-018150
2020-05-22 S, Open-market sale Moderna, Inc.MRNA 4 lines 34,772,245, disposed Open Form 4 filing 0000899243-20-014188
2020-05-21 S, Open-market sale Moderna, Inc.MRNA 12 lines 33,447,031, disposed Open Form 4 filing 0000899243-20-014188
2020-05-18 P, Open-market purchase Axcella Health Inc.AXLA 3 lines 18,050,000, acquired Open Form 4 filing 0000899243-20-013708
2019-12-11 S, Open-market sale Moderna, Inc.MRNA 2 lines 4,445,457, disposed Open Form 4 filing 0000899243-19-028975
2019-12-10 S, Open-market sale Moderna, Inc.MRNA 2 lines 481,871, disposed Open Form 4 filing 0000899243-19-028975
2019-12-09 S, Open-market sale Moderna, Inc.MRNA 2 lines 3,269,607, disposed Open Form 4 filing 0000899243-19-028975
2019-05-13 P, Open-market purchase Axcella Health Inc.AXLA 10,000,000, acquired Open Form 4 filing 0001104659-19-029735
2018-05-11 P, Open-market purchase Evelo Biosciences, Inc.EVLO 4,500,000, acquired Open Form 4 filing 0000899243-18-013014
2016-09-23 S, Open-market sale Eleven Biotherapeutics, Inc.EBIO 4 lines 208,856, disposed Open Form 4 filing 0001012975-16-001507
2016-09-22 S, Open-market sale Eleven Biotherapeutics, Inc.EBIO 597,123, disposed Open Form 4 filing 0001012975-16-001507
2016-09-22 S, Open-market sale Eleven Biotherapeutics, Inc.EBIO 358,485, disposed Open Form 4 filing 0001012975-16-001507
2016-09-22 S, Open-market sale Eleven Biotherapeutics, Inc.EBIO 149,275, disposed Open Form 4 filing 0001012975-16-001507

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Flagship Ventures Fund IV-Rx, L.P., insider transactions. Retrieved 2026-08-22 from https://ebomi.com/insider/0001590973

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.